Alcohol use disorder, Depression
Conditions
Brief summary
The primary outcome is the difference in the change in MADRS from baseline to within three days from the final treatment session between intervention group and control group
Detailed description
Assess group differences in the change in alcohol craving from baseline, Assess changes in alcohol consumption (measured by average number of alcohol units per week and percentage of days abstinent) from three months prior to admission until six-months post-treatment, Assess frequency, severity and duration of ARs/SARs, Assess and compare between groups tolerability for each treatment session (participant- and physician-reported tolerability), Assess within- and between-group changes in neurocognitive function from baseline to within three days from the final treatment session
Interventions
DRUGMidazolam Accord 1 mg/ml
DRUGinjeksjonsvæske/infusjonsvæske
DRUGoppløsning
DRUGKetalar 50 mg/ml injeksjonsvæske
Sponsors
University Hospital Of North Norway HF
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Assess group differences in the change in alcohol craving from baseline, Assess changes in alcohol consumption (measured by average number of alcohol units per week and percentage of days abstinent) from three months prior to admission until six-months post-treatment, Assess frequency, severity and duration of ARs/SARs, Assess and compare between groups tolerability for each treatment session (participant- and physician-reported tolerability), Assess within- and between-group changes in neurocognitive function from baseline to within three days from the final treatment session | — |
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the difference in the change in MADRS from baseline to within three days from the final treatment session between intervention group and control group | — |
Countries
Norway
Outcome results
None listed